时事通讯“IP & Technology Newsletter Vol.1 (2025)”发布。
Contents
・The court ruled on whether the scope of the patent, extended based on an innovator drug containing dasatinib hydrate as the active ingredient, also covers the generic drug containing dasatinib anhydride as the active ingredient.
(Tokyo District Court Judgment on May 15, 2025 (2023 (Wa) No. 70527: Case Seeking Declaratory Judgment, 2024 (Wa) No. 70016: Case of Counterclaim for Damages))